Pasithea Therapeutics Corp. — Director's Dealing 2022

Nov 17, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Pasithea Therapeutics Corp. (KTTA)
CIK: 0001841330
Period of Report: 2022-11-15

Reporting Person: Dumesnil Simon (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-11-15	Common Stock	A	10000	$1.07	Acquired	10000	Direct
2022-11-17	Common Stock	A	40000	$1.06	Acquired	50000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-08-02	Stock Option (to acquire Common Stock)	$6.00	A	100000	Acquired	2031-08-02	Common Stock (100000)	Direct

Footnotes

F1: The Reporting Person was granted 100,000 stock options which have a ten-year term. The option is vested and exercisable with regard to 50,000 shares of Common Stock. The remaining 50% vest, subject to Mr. Dumesnil's remaining employed and in good standing, on August 2, 2023.